
A domestically developed therapy has entered South Korea’s obesity treatment market, long dominated by imported products such as Wegovy and Mounjaro. Hanmi Pharmaceutical’s in-house developed ‘Epe’ has secured approval from the Ministry of Food and Drug Safety (MFDS), marking South Korea’s first homegrown glucagon-like peptide-1 (GLP-1) class obesity treatment and its 45th domestic new drug overall.
The MFDS announced on October 7 that it approved Hanmi Pharmaceutical’s ‘Epe Auto-Injector Injection’ in 2, 4, 6, 8, and 10 mg doses (active ingredient: epeglenatide).
Challenging an Import-Dominated Market
South Korea’s GLP-1 obesity treatment market has expanded rapidly following the domestic arrivals of Novo Nordisk’s Wegovy and Eli Lilly’s Mounjaro, which swiftly shifted the treatment landscape toward GLP-1 receptor agonists. With the approval of a Korean-made GLP-1 therapy, industry observers are watching closely to see whether the import-led market dynamic will shift.
Epe is indicated for chronic weight management in adults with obesity or overweight without diabetes, serving as an adjunct to a reduced-calorie diet and increased physical activity. As a GLP-1 receptor agonist, Epe mimics the gut hormone secreted after eating to regulate blood sugar and appetite. The drug targets GLP-1 receptors in the brain and gastrointestinal tract to suppress appetite and delay gastric emptying, helping patients sustain satiety for longer periods.
Tailored Regulatory Review Process
Under the new marketing authorization and review framework established last year, the MFDS formed a dedicated 19-member review team—including specialized reviewers—to evaluate Epe. The regulatory authority assessed compliance with Good Clinical Practice (GCP) and Good Manufacturing Practice (GMP) standards while conducting tailored, in-person consultations with Hanmi Pharmaceutical after the marketing authorization application was submitted.
"We will continue to improve the predictability, transparency, and speed of our regulatory reviews so that treatments with demonstrated safety and efficacy can be delivered to patients promptly," an MFDS official said.